160 related articles for article (PubMed ID: 8902056)
1. Identification of the genes encoding cancer antigens: implications for cancer immunotherapy.
Rosenberg SA; Kawakami Y; Robbins PF; Wang R
Adv Cancer Res; 1996; 70():145-77. PubMed ID: 8902056
[No Abstract] [Full Text] [Related]
2. Cancer vaccines based on the identification of genes encoding cancer regression antigens.
Rosenberg SA
Immunol Today; 1997 Apr; 18(4):175-82. PubMed ID: 9136454
[No Abstract] [Full Text] [Related]
3. The immunotherapy of solid cancers based on cloning the genes encoding tumor-rejection antigens.
Rosenberg SA
Annu Rev Med; 1996; 47():481-91. PubMed ID: 8712798
[TBL] [Abstract][Full Text] [Related]
4. Cloning and characterization of the genes encoding the murine homologues of the human melanoma antigens MART1 and gp100.
Zhai Y; Yang JC; Spiess P; Nishimura MI; Overwijk WW; Roberts B; Restifo NP; Rosenberg SA
J Immunother; 1997 Jan; 20(1):15-25. PubMed ID: 9101410
[TBL] [Abstract][Full Text] [Related]
5. A peptide recognized by human cytolytic T lymphocytes on HLA-A2 melanomas is encoded by an intron sequence of the N-acetylglucosaminyltransferase V gene.
Guilloux Y; Lucas S; Brichard VG; Van Pel A; Viret C; De Plaen E; Brasseur F; Lethé B; Jotereau F; Boon T
J Exp Med; 1996 Mar; 183(3):1173-83. PubMed ID: 8642259
[TBL] [Abstract][Full Text] [Related]
6. Identification of tumor-regression antigens in melanoma.
Kawakami Y; Robbins PF; Wang RF; Rosenberg SA
Important Adv Oncol; 1996; ():3-21. PubMed ID: 8791125
[No Abstract] [Full Text] [Related]
7. Genes coding for tumor rejection antigens: perspectives for specific immunotherapy.
Boon T; Coulie P; Marchand M; Weynants P; Wölfel T; Brichard V
Important Adv Oncol; 1994; ():53-69. PubMed ID: 8206495
[No Abstract] [Full Text] [Related]
8. Development of cancer immunotherapies based on identification of the genes encoding cancer regression antigens.
Rosenberg SA
J Natl Cancer Inst; 1996 Nov; 88(22):1635-44. PubMed ID: 8931607
[TBL] [Abstract][Full Text] [Related]
9. Progress in the development of immunotherapy for the treatment of patients with cancer.
Rosenberg SA
J Intern Med; 2001 Dec; 250(6):462-75. PubMed ID: 11902815
[TBL] [Abstract][Full Text] [Related]
10. Isolation of a new melanoma antigen, MART-2, containing a mutated epitope recognized by autologous tumor-infiltrating T lymphocytes.
Kawakami Y; Wang X; Shofuda T; Sumimoto H; Tupesis J; Fitzgerald E; Rosenberg S
J Immunol; 2001 Feb; 166(4):2871-7. PubMed ID: 11160356
[TBL] [Abstract][Full Text] [Related]
11. Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection.
Kawakami Y; Eliyahu S; Delgado CH; Robbins PF; Sakaguchi K; Appella E; Yannelli JR; Adema GJ; Miki T; Rosenberg SA
Proc Natl Acad Sci U S A; 1994 Jul; 91(14):6458-62. PubMed ID: 8022805
[TBL] [Abstract][Full Text] [Related]
12. Human tumor antigens for cancer vaccine development.
Wang RF; Rosenberg SA
Immunol Rev; 1999 Aug; 170():85-100. PubMed ID: 10566144
[TBL] [Abstract][Full Text] [Related]
13. Human tumour antigens recognized by T-cells: perspectives for new cancer vaccines.
Van den Eynde B; Gaugler B; van der Bruggen P; Coulie P; Brichard V; Boon T
Biochem Soc Trans; 1995 Aug; 23(3):681-6. PubMed ID: 8566443
[No Abstract] [Full Text] [Related]
14. Tumor antigens isolated from a patient with vitiligo and T-cell-infiltrated melanoma.
Kiniwa Y; Fujita T; Akada M; Ito K; Shofuda T; Suzuki Y; Yamamoto A; Saida T; Kawakami Y
Cancer Res; 2001 Nov; 61(21):7900-7. PubMed ID: 11691810
[TBL] [Abstract][Full Text] [Related]
15. Cloning of a new gene encoding an antigen recognized by melanoma-specific HLA-A24-restricted tumor-infiltrating lymphocytes.
Robbins PF; el-Gamil M; Li YF; Topalian SL; Rivoltini L; Sakaguchi K; Appella E; Kawakami Y; Rosenberg SA
J Immunol; 1995 Jun; 154(11):5944-50. PubMed ID: 7751637
[TBL] [Abstract][Full Text] [Related]
16. Induction of tumor-reactive CTL from peripheral blood and tumor-infiltrating lymphocytes of melanoma patients by in vitro stimulation with an immunodominant peptide of the human melanoma antigen MART-1.
Rivoltini L; Kawakami Y; Sakaguchi K; Southwood S; Sette A; Robbins PF; Marincola FM; Salgaller ML; Yannelli JR; Appella E
J Immunol; 1995 Mar; 154(5):2257-65. PubMed ID: 7868898
[TBL] [Abstract][Full Text] [Related]
17. The Antigenicity of the Tumor Cell - Context Matters.
Kristensen VN
N Engl J Med; 2017 Feb; 376(5):491-493. PubMed ID: 28146670
[No Abstract] [Full Text] [Related]
18. Identification of new melanoma epitopes on melanosomal proteins recognized by tumor infiltrating T lymphocytes restricted by HLA-A1, -A2, and -A3 alleles.
Kawakami Y; Robbins PF; Wang X; Tupesis JP; Parkhurst MR; Kang X; Sakaguchi K; Appella E; Rosenberg SA
J Immunol; 1998 Dec; 161(12):6985-92. PubMed ID: 9862734
[TBL] [Abstract][Full Text] [Related]
19. Peptide-specific CTL in tumor infiltrating lymphocytes from metastatic melanomas expressing MART-1/Melan-A, gp100 and Tyrosinase genes: a study in an unselected group of HLA-A2.1-positive patients.
Spagnoli GC; Schaefer C; Willimann TE; Kocher T; Amoroso A; Juretic A; Zuber M; Luscher U; Harder F; Heberer M
Int J Cancer; 1995 Oct; 64(5):309-15. PubMed ID: 7591302
[TBL] [Abstract][Full Text] [Related]
20. MHC class II restricted neoantigen: A promising target in tumor immunotherapy.
Sun Z; Chen F; Meng F; Wei J; Liu B
Cancer Lett; 2017 Apr; 392():17-25. PubMed ID: 28104443
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
